natgillin/translations-raw huggingface dataset:
Patients receiving Betaferon showed a reduction in frequency (30%) and severity of clinical relapses, as well as the number of hospitalisations due to disease. 
Bolniki, ki so prejemali zdravilo Betaferon, so imeli manj pogoste (30 %) in manj hude klinične recidive in so bili redkeje hospitalizirani zaradi bolezni.
If reactions are severe, Betaferon should be discontinued and appropriate medical intervention instituted. 
Če so reakcije hude, je treba prenehati zdravljenje z zdravilom Betaferon in ustrezno ukrepati.
Patients should be started at 62.5 microgram (0.25 ml) subcutaneously every other day, and increased slowly to a dose of 250 microgram (1.0 ml) every other day (see Table A). 
Zdravljenje je treba začeti z odmerkom 62,5 mikrogramov (0,25 ml) subkutano vsak drugi dan, nato pa ga počasi povečevati do odmerka 250 mikrogramov (1 ml) vsak drugi dan (glejte preglednico A).
10 - Hold the syringe assembly at the bottom of the vial. 
10 - Sklop brizge držite na dnu viale.
Betaferon should also be used with caution in patients who suffer from pre-existing cardiac disorders. 
Zdravilo Betaferon je treba previdno uporabljati pri bolnikih, ki že imajo srčno bolezen.
Removing the vial and adapter from the syringe ensures that the solution will flow out from the needle when injected. 
Če vialo in adapter odstranite z brizge, boste zagotovili, da bo raztopina pri injiciranju tekla iz igle.
In both trials secondary progressive multiple sclerosis patients receiving Betaferon showed a reduction in frequency (30%) of clinical relapses. 
V obeh preskušanjih se je pri bolnikih s sekundarno progresivno multiplo sklerozo, ki so prejemali zdravilo Betaferon, pogostnost kliničnih recidivov zmanjšala (30 %).
Retrospective analyses in subgroups showed that a treatment effect on disability progression is most likely in patients with active disease before treatment commences (Hazard Ratio 0.72, 95% confidence interval (0.59, 0.88), p=0.0011, corresponding to a 28 % risk reduction due to Betaferon in patients with relapses or pronounced EDSS progression, 8.0 million IU Betaferon versus all placebo patients). 
Retrospektivne analize podskupin so pokazale, da je učinek zdravljenja na napredovanje invalidnosti najverjetnejši pri bolnikih, ki imajo aktivno bolezen, preden se začne zdravljenje (razmerje ogroženosti = 0,72, 95-% interval zaupanja (0,59, 0,88), p = 0,0011, kar ustreza 28 % zmanjšanju tveganja zaradi zdravila Betaferon pri bolnikih s poslabšanjem bolezenskih znakov ali izrazitim napredovanjem glede na EDSS, ki so dobivali 8,0 milijonov i.e. zdravila Betaferon v primerjavi z vsemi bolniki, ki so prejemali placebo).
The treatment with Betaferon should be initiated under the supervision of a physician experienced in the treatment of the disease. 
Zdravljenje z zdravilom Betaferon je treba začeti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem te bolezni.
‘How to use Betaferon'). 
Kako uporabljati zdravilo Betaferon).
• Sodium - this medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodium-free'. 
• natrij - to zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na 1 ml, kar v bistvu pomeni ‘brez natrija'.
During the post-marketing period very rare reports have been received of worsening of cardiac status in patients with pre-existing significant cardiac disease temporarily associated with the initiation of Betaferon therapy. 
V obdobju trženja so zelo redko poročali o prehodnem poslabšanju srčne bolezni pri bolnikih s pomembno srčno boleznijo v anamnezi, ki je bilo povezano z uvedbo zdravljenja z zdravilom Betaferon.
Metabolism and nutrition disorders Blood glucose decreased (<55 mg/dl) × 
Presnovne in prehranske motnje zmanjšana vrednost glukoze (< 55 mg/dl) ×
When you use the solution, warm it up in your hands before injecting to avoid pain. 
Injekcijo pred injiciranjem segrejte med dlanmi, da preprečite bolečino.
Important: Do not use any area where you can feel lumps, bumps, firm knots, pain or an area that is discoloured, indented, scabbed, or where the skin is broken. 
Pomembno: Ne uporabljajte predelov, na katerih čutite zatrdline, bulice, čvrste vozliče, predelov, ki so boleči, ali predelov, na katerih je koža spremenjena, vdrta, pokrita s krastami ali ranjena.
Flu-like symptoms may also be reduced by administration of non-steroidal anti-inflammatory drugs. 
Gripi podobni simptomi se lahko zmanjšajo z uporabo nesteroidnih protivnetnih zdravil.
The recommended dose of Betaferon is 250 microgram (8.0 million IU), contained in 1 ml of the reconstituted solution (see section 6.6), to be injected subcutaneously every other day. 
Priporočeni odmerek zdravila Betaferon je 250 mikrogramov (8,0 milijonov i.e.), kolikor ga vsebuje 1 ml rekonstituirane raztopine (glejte poglavje 6.6), ki ga je treba injicirati subkutano vsak drugi dan.
If foam is present -- which can happen if the vial is shaken or swirled too much - let the vial sit undisturbed until the foam settles. 
Če je v viali pena, kar se lahko zgodi, če jo premočno pretresete ali zavrtite, pustite vialo mirovati, da pena izgine.
NOTE: The injection should be administered immediately after mixing (if the injection is delayed, refrigerate the solution and inject it within 3 hours). 
OPOMBA: Raztopino si injicirajte nemudoma po pripravi (če to ni možno, raztopino shranite v hladilnik in si jo injicirajte v 3 urah).
Patients who develop neutropenia should be monitored closely for the development of fever or infection. 
Bolnike, pri katerih se pojavi nevtropenija, je treba pozorno spremljati glede morebitnega zvišanja telesne temperature ali pojava okužb.
If you forget to use Betaferon 
Če ste pozabili uporabiti zdravilo Betaferon
The incidence of injection site reactions may be reduced by the use of an autoinjector. 
Pogostnost reakcij na mestu injiciranja se lahko zmanjša z uporabo avtoinjektorja.
This medicinal product contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na 1 ml, kar v bistvu pomeni »brez natrija«.
No individual sale of single packs. 
Posamezna pakiranja niso za prodajo.
Risk reduction Hazard ratio with 95% confidence interval log-rank test 
Razmerje tveganja s 95-% intervalom zaupanja
Interferon beta-1b has been shown to possess both antiviral and immunoregulatory activities. 
Dokazano je, da interferon beta-1b deluje protivirusno in imunoregulacijsko.
The following adverse event listing is based on reports from clinical trials (Table 1, adverse events and laboratory abnormalities) and from the post-marketing surveillance (Table 2, frequencies - where known- based on pooled clinical trials (very common ≥1/10, common ≥1/100 to <1/10, uncommon ≥ 1/1,000 to < 1/100, rare ≥1/10,000 to <1/1,000, very rare < 1/10,000)) of Betaferon use. 
Spodnja seznama neželenih učinkov temeljita na poročilih iz kliničnih preskušanj (preglednica 1, neželeni učinki in nenormalni izvidi laboratorijskih preiskav) in spremljanj iz obdobja trženja zdravila Betaferon (preglednica 2, pogostnosti - kjer so znane - glede na združene podatke iz kliničnih preskušanj (zelo pogosti ≥ 1/10, pogosti ≥ 1/100 do <1/10, občasni ≥ 1/1.000 do < 1/100, redki ≥ 1/10.000 do < 1/1.000, zelo redki < 1/10.000)).
Other medicines and Betaferon 
Druga zdravila in zdravilo Betaferon
During Betaferon treatment you are likely to experience injection site reactions. 
Med zdravljenjem z zdravilom Betaferon se bodo verjetno pojavile reakcije na mestu injiciranja.
No separate investigations were performed regarding the influence of Betaferon on the cardiovascular system, respiratory system and the function of endocrine organs. 
Posebnih študij o vplivu zdravila Betaferon na srce in ožilje, dihala in delovanje endokrinih organov niso izvedli.
Betaferon should be used with caution with: - medicines which need a certain liver enzyme system (known as cytochrome P450 system) for their removal from the body, for example medicines used to treat epilepsy (like phenytoin). 
- zdravili, ki potrebujejo določen jetrni encimski sistem (t.i. sistem citokrom P450) za odstranitev iz telesa, na primer z zdravili, ki se uporabljajo za zdravljenje epilepsije (kot je fenitoin),
187.5 microgram 
187,5 mikrogramov
Be sure that the orange tip cap is firmly attached to the solvent syringe! 
Prepričajte se, da je oranžni pokrov trdno pritrjen na brizgo z vehiklom.
There are follow-up data under controlled clinical conditions for patients with relapsing-remitting MS for up to 5 years and for patients with secondary progressive MS for up to 3 years. 
Za bolnike z recidivno-remitentno multiplo sklerozo obstajajo podatki o spremljanju v nadzorovanih kliničnih pogojih za obdobje do 5 let, za bolnike s sekundarno progresivno multiplo sklerozo za obdobje do 3 let.
Separate Annex: INTRODUCTORY LEAFLET FOR TITRATION PACK 
Posebna priloga: NAVODILO ZA UPORABO SETA ZA TITRIRANJE
RR-MS, SP-MS and single clinical event suggestive of MS Betaferon was effective in all multiple sclerosis studies to reduce disease activity (acute inflammation in the central nervous system and permanent tissue alterations) as measured by magnetic resonance imaging (MRI). 
RR-MS, SP-MS in enkratni demielinizacijski dogodek, ki nakazuje multiplo sklerozo Zdravilo Betaferon je v vseh študijah multiple skleroze učinkovito zmanjšalo aktivnost bolezni (akutno vnetje v osrednjem živčevju in trajne spremembe tkiva), merjeno z magnetnoresonančnim slikanjem (MRS).
Work through each rotation cycle in turn. 
Zaporedoma upoštevajte vse rotacijske cikle.
Interferon alpha, interferon beta, and interferon gamma have overlapping yet distinct biologic activities. 
Interferoni alfa, beta in gama imajo prekrivajoče se, vendar med seboj različno biološko delovanje.
Two controlled clinical trials with Betaferon involving a total of 1,657 patients with secondary progressive multiple sclerosis (baseline EDSS 3 to 6.5, i.e. patients were able to walk) were performed. 
1657 bolnikov s sekundarno progresivno multiplo sklerozo (izhodiščni EDSS 3 do 6,5, tj. bolniki so lahko hodili).
Push it down firmly until you feel it snap into place on the vial. 
Potisnite ga navzdol, dokler ne začutite, da je skočil v pravi položaj.
This might happen several weeks to several years after starting Betaferon. 
To se lahko pojavi nekaj tednov do nekaj let po začetku zdravljenja z zdravilom Betaferon.
It is best to use your thumb rather than your nail as it could break. 
Ne odpirajte je z nohtom, ker se lahko zlomi.
The most serious events often occurred in patients exposed to other drugs or substances known to be associated with hepatotoxicity or in the presence of comorbid medical conditions (e.g. metastasising malignant disease, severe infection and sepsis, alcohol abuse). 
Najbolj resni neželeni učinki so se pogosto pojavili pri bolnikih, ki so prejemali še druga zdravila ali snovi z znanimi hepatotoksičnimi učinki in pri bolnikih s sočasnimi boleznimi (npr. metastatsko maligno boleznijo, hudo okužbo in sepso, zlorabo alkohola).
Triple pack 4 
Tridelno pakiranje 4
16 - Next, hold the blue vial adapter with the attached vial and remove it from the syringe by twisting it and then pulling it down, away from the syringe. 
16 - Nato primite modri adapter za vialo na katerem je pritrjena viala in ga odstranite z brizge tako, da ga zavrtite in nato povlečete stran od brizge.
In MS, inflammation destroys the protective sheath (called myelin) around the nerves of the CNS and stops the nerves from working properly. 
Pri MS vnetje uniči zaščitno ovojnico (imenovano mielinska ovojnica), ki obdaja živce v osrednjem živčevju in prepreči njihovo pravilno delovanje.
5 - Holding the syringe like a pencil or a dart, push the needle straight into the skin at a 90˚ angle with a quick, firm motion. 
5 - Brizgo primite kot svinčnik ali puščico za pikado in iglo s hitrim, odločnim gibom zapičite naravnost v kožo pod kotom 90˚.
The effect of alternate-day administration of 250 microgram (8.0 million IU) of Betaferon on drug metabolism in multiple sclerosis patients is unknown. 
Učinek uporabe 250 mikrogramov (8,0 milijonov i.e.) zdravila Betaferon vsak drugi dan na presnovo zdravil pri bolnikih z multiplo sklerozo ni znan.
Injection site reactions may occur less frequently, if you use an auto-injector device. 
Reakcije na mestu injiciranja so lahko redkejše, če uporabljate avtoinjektor.
If your depression and/or suicidal thoughts are severe, you will not be prescribed Betaferon (see also ‘Do not use Betaferon'). 
Če so vaša depresija in/ali samomorilne misli resne, vam ne bodo predpisali zdravila Betaferon (glejte tudi poglavje Ne uporabljajte zdravila Betaferon).
The two studies showed inconsistent results for the primary endpoint time to confirmed progression, representing delay of disability progression: 
Izsledki obeh preskušanj niso usklajeni glede primarnega končnega izida, tj. čas do potrjene progresije bolezni, kar pomeni odložitev napredovanja invalidnosti.
In patients with a single clinical event suggestive of multiple sclerosis, the progression to clinically definite multiple sclerosis was significantly delayed over a period of five years. 
Pri bolnikih z enim samim kliničnim dogodkom, ki nakazuje multiplo sklerozo, je bilo v obdobju petih let napredovanje do klinično potrjene multiple skleroze pomembno upočasnjeno.
Pulmonary arterial hypertension has been seen at various time points during treatment, including several years after starting treatment with Betaferon. 
Pljučna arterijska hipertenzija se lahko pojavi ob različnih časovnih točkah zdravljenja, lahko tudi nekaj let po začetku zdravljenja z zdravilom Betaferon.
10 - 15 cm from groin 
10-15 cm od komolca
List 2: Side effects reported on the marketed product (from spontaneous reporting, frequencieswhere known - based on clinical trials) 
Seznam 2: Neželeni učinki iz obdobja trženja zdravila (iz spontanih poročil, pogostnosti - kjer so znane - glede na podatke iz kliničnih preskušanj)
HR = 0.76 [0.52, 1.11] 
RT = 0,76 [0,52; 1,11]
17 - Dispose of the vial and any unused portion of the solution in the disposal unit 
17 - Vialo in neporabljen del raztopine zavrzite v posodo za odpadke.
These blood clots could affect your kidneys. 
Ti krvni strdki lahko vplivajo na delovanje ledvic.
− if you notice pain in your belly which is radiating to your back, and/or you feel sick or have a fever. 
- če imate bolečine v trebuhu, ki se širijo v hrbet, in/ali vam je slabo ali imate zvišano telesno temperaturo.
One of the two studies demonstrated a statistically significant delay in the time to disability progression (Hazard Ratio = 0.69, 95% confidence interval (0.55, 0.86), p=0.0010, corresponding to a 31% risk reduction due to Betaferon) and in the time to becoming wheelchair bound (Hazard Ratio = 0.61, 95% confidence interval (0.44, 0.85), p=0.0036, corresponding to a 39% risk reduction due to Betaferon) in patients who received Betaferon. 
Prva od njiju je pri bolnikih, ki so prejemali zdravilo Betaferon, ugotovila statistično značilno odložitev do napredovanja invalidnosti (razmerje ogroženosti = 0,69, 95-% interval zaupanja (0,55, 0,86), p = 0,0010, kar ustreza 31 % zmanjšanju tveganja zaradi zdravila Betaferon) in priklenjenosti na invalidski voziček (razmerje ogroženosti = 0,61, 95-% interval zaupanja (0,44, 0,85), p = 0,0036, kar ustreza 39 % zmanjšanju tveganja zaradi zdravila Betaferon).
Table 1: Adverse events and laboratory abnormalities with incidence rates ≥ 10% and the respective percentages under placebo; significantly associated side effects < 10% based on reports from clinical trials 
Preglednica 1: Neželeni učinki in nenormalni izvidi laboratorijskih preiskav s pogostnostjo ≥ 10 % in ustrezni odstotki pri placebu; glede na poročila iz kliničnih preskušanj jih je z zdravilom pomembno povezanih <10 %
► Choosing an injection site 
► Izbira mesta injiciranja
No primary endpoint 
Ni primarnega končnega izida
Betaferon may also be administered with a suitable autoinjector. 
Zdravilo Betaferon se lahko uporabi tudi z ustreznim avtoinjektorjem.
Triple pack 2 
Tridelno pakiranje 2
0.25 ml for first three injections (at day 1, 3, 5 of therapy), or 0.5 ml for the injections at day 7, 9, 11 of therapy, or 0.75 ml for the injections at day 13, 15, 17 of therapy. 
0,25 ml za prva tri injiciranja (1., 3. in 5. dan zdravljenja) ali 0,5 ml za injiciranje na 7., 9. in 11. dan zdravljenja ali 0,75 ml za injiciranje na 13., 15. in 17. dan zdravljenja.
General disorders and administration site conditions Serious hypersensitivity reactions (rare but severe acute reactions such as bronchospasm, anaphylaxis and urticaria) may occur. 
Lahko se pojavijo resne preobčutljivostne reakcije (redke, vendar hude akutne reakcije, kot je bronhospazem, anafilaksija in urtikarija).
If an area becomes sore, talk to your doctor or nurse about choosing other injection sites. 
Če vas predel začne boleti, se posvetujte z zdravnikom ali medicinsko sestro o drugih mestih injiciranja.
3-month pack comprising 45 (3x15) single packs, each containing: 3-month pack comprising 42 (3x14) single packs, each containing: 2-month pack comprising 28 (2x14) single packs, each containing: I. 
3-mesečno pakiranje s 45 (3 x 15) posameznimi pakiranji, vsako vsebuje: 3-mesečno pakiranje z 42 (3 x 14) posameznimi pakiranji, vsako vsebuje: 2-mesečno pakiranje z 28 (2 x 14) posameznimi pakiranji, vsako vsebuje:
Year 5 results Open-label follow-up 
Izsledki v petem letu odprtega nadaljevanja študije
Treatment with Betaferon should be started under the supervision of a doctor who is experienced in the treatment of multiple sclerosis. 
Kako uporabljati zdravilo Betaferon Zdravljenje z zdravilom Betaferon je treba začeti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem multiple skleroze.
At the beginning of treatment adverse reactions are common but in general they subside with further treatment. 
Na začetku zdravljenja so neželeni učinki pogosti, a z nadaljevanjem zdravljenja praviloma izzvenijo.
The following side effects listing is based on reports from clinical trials with Betaferon (list 1) and from side effects reported on the marketed product (list 2). 
Naslednji seznam neželenih učinkov temelji na poročilih iz kliničnih preskušanj z zdravilom Betaferon (seznam 1) in neželenih učinkih, o katerih so poročali po začetku trženja zdravila
To increase tolerability of Betaferon, a dose titration was applied and non-steroidal anti-inflammatory drugs were administered at start of therapy. 
Da bi izboljšali bolnikovo prenašanje zdravila Betaferon so odmerek titrirali, na začetku zdravljenja pa so uporabili nesteroidna protivnetna zdravila.
For a description of how to prepare and use the Betaferon powder, please refer to section 3. 
Za navodila kako pripraviti in uporabiti zdravilo Betaferon, glejte poglavje 3.
62.5 microgram 
62,5 mikrogramov
Contents of the pack and other information Annex - self injection procedure 
Shranjevanje zdravila Betaferon Vsebina pakiranja in dodatne informacije Dodatek - postopek samoinjiciranja
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, pharmacist or nurse. 
Če kateri koli neželeni učinek postane resen ali če opazite kateri koli neželeni učinek, ki ni omenjen v tem navodilu, obvestite zdravnika,
► who suffer from secondary progressive multiple sclerosis with active disease shown by relapses. 
► s sekundarno progresivno multiplo sklerozo, ki imajo aktivno bolezen, kar se kaže z relapsi.
One controlled clinical trial with Betaferon in patients with relapsing-remitting multiple sclerosis and able to walk unaided (baseline EDSS 0 to 5.5) was performed. 
Izvedeno je bilo eno nadzorovano klinično preskušanje z zdravilom Betaferon pri bolnikih z recidivno remitentno multiplo sklerozo, ki so lahko hodili brez pomoči (izhodiščni EDSS 0 do 5,5).
One way to do that is to note the injection site on the enclosed medication record card. 
Ena možnost za vodenje takšne evidence je zapisovanje na priloženo kartico o uporabi zdravila.
Laboratory findings suggestive of TMA include decreased platelet counts, increased serum lactate dehydrogenase (LDH) due to haemolysis and schistocytes (erythrocyte fragmentation) on a blood film. 
Laboratorijski izvidi, ki kažejo na TMA, vključujejo zmanjšano število trombocitov, povečano koncentracijo laktat-dehidrogenaze v serumu (LDH) zaradi hemolize in shistocite (fragmentirane eritrocite) v krvnem razmazu.
Interferon beta-1b both decreases the binding affinity and enhances the internalisation and degradation of the interferon-gamma receptor. 
Interferon beta-1b zmanjša vezavno afiniteto receptorja interferona gama in poveča njegovo internalizacijo in degradacijo.
The absolute bioavailability of subcutaneously administered interferon beta-1b was approximately 
Absolutna biološka uporabnost subkutano uporabljenega interferona beta-1b je bila 50 %.
Remove the tip cap by twisting it off. 
Odstranite pokrov z obračanjem in ga zavrzite.
Annex: SELF-INJECTION PROCEDURE 
Dodatek: POSTOPEK SAMOINJICIRANJA
Release the plunger, which may go back to its original position. 
Morda se bo vrnil v prvotni položaj.
From various studies mean clearance rates and half-lives of disposition phases from serum were estimated to be at most 30 ml·min-1·kg-1 and 5 hours, respectively. 
Na osnovi različnih študij je bil ocenjeni povprečni očistek največ 30 ml·min-1·kg-1, razpolovni čas faze porazdelitve iz seruma pa 5 ur.
0.25 ml for first three injections (at day 1, 3 and 5 of therapy). 
0,25 ml za prva tri injiciranja (na 1., 3. in 5. dan zdravljenja)
What Betaferon is and what it is used for What you need to know before you use Betaferon How to use Betaferon 
Kaj je zdravilo Betaferon in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Betaferon Kako uporabljati zdravilo Betaferon
The syringes in this titration pack are marked accordingly with the appropriate doses (0.25; 0.5; 0.75 or 1.0 ml). 
Brizge v tem setu za titriranje so ustrezno označene z odmerki (0,25; 0,5; 0,75 in 1 ml).
• patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis (see section 5.1). 
• bolnikov z enkratnim demielinizacijskim dogodkom, z aktivnim vnetnim procesom, če je dovolj resen, da je potrebno intravensko zdravljenje s kortikosteroidi, če je bila alternativna diagnoza izključena in če je ugotovljeno, da je tveganje za razvoj klinično potrjene multiple skleroze veliko (glejte poglavje 5.1), • bolnikov z recidivno-remitentno multiplo sklerozo (RR-MS), ki so v zadnjih dveh letih imeli dva recidiva ali več,
4 - Open the blister pack containing the vial adapter, but leave the vial adapter inside. 
4 - Odprite pretisni omot z adapterjem za vialo, vendar ga pustite v omotu.
To prepare your injection, turn the assembly over so that the vial is on top, cap side pointing down. 
Za pripravo injekcije sklop obrnite, tako da je viala na vrhu, pokrovček pa obrnjen navzdol.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING TITRATION PACK WITH 4x1 TRIPLE PACK (3 VIALS/3 PRE-FILLED SYRINGES), FOR FIRST 12 INJECTIONS/TREATMENT DAYS (INCLUDING BLUE BOX) 
SET ZA TITRIRANJE S 4 X 1 TRIDELNIM PAKIRANJEM (3 VIALE / 3 NAPOLNJENE INJEKCIJSKE BRIZGE), ZA PRVIH 12 INJICIRANJ / DNI ZDRAVLJENJA (S PODATKI ZA »BLUE-BOX«)
Skin breakdown and tissue damage (necrosis) around the injection site are reported less frequently. 
Redkeje poročajo o primerih razkroja kože in poškodbe tkiva (nekroza) okoli mesta injiciranja.
What Betaferon is used for 
Za kaj se uporablja zdravilo Betaferon
Leave the wipe on top of the vial. 
Na koncu blazinico pustite na vrhu viale.
By following this sequence, you will give each area a chance to recover before receiving another injection. 
Z upoštevanjem tega zaporedja omogočite, da si mesta injiciranja opomorejo pred naslednjo injekcijo.